Dataset Information

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

ABSTRACT:

Background

Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome.

Aim

To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone).

Methods

The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient's current antipsychotic for 12 weeks. The primary outcome measure was mean change in weight, while secondary outcome measures included change in waist circumference; fasting blood glucose; HbA1c; triglycerides; total, HDL and LDL cholesterol levels; functioning; and neurocognition.

Results

For the overall study (n = 55), there was no significant effect of adjunct aripiprazole on the weight of the subjects. However, the clozapine group achieved significant weight loss (p = 0.002) and also had significant improvements in total cholesterol (p < 0.001), HDL (p = 0.016), LDL (p = 0.044) and triglyceride levels (p = 0.038). The olanzapine group had significant improvement in triglycerides (p = 0.001), and other metabolic parameters for this group showed improvement trends, but did not reach statistical significance. The risperidone group did not show any significant improvement in weight or metabolic parameters.

Conclusions

The study adds support to the adjunctive use of aripiprazole to clozapine for weight loss and improvement in metabolic profile, and for reduction in cardiometabolic risk for patients on olanzapine.

Trial registration

Clinicaltrials.gov identifier: NCT02949752.

SUBMITTER: Gupta B

PROVIDER: S-EPMC8504280 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

Gupta Bhanu B Chee Kok-Seng KS Neo Li-Qi LQ Tang Charmaine C Hariram Jayaraman J Tan Geoffrey Chern-Yee GC Verma Swapna S Basu Sutapa S Appan Deva-Priya DP Ting Chan-Chun CC Abdin Edimansyah E Lee Jimmy J

Therapeutic advances in psychopharmacology 20211009

<h4>Background</h4>Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome.<h4>Aim</h4>To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone).<h4>Methods</h4>The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient's current antipsychotic for 12 weeks. The primary outcome measure ...[more]

PMID: 34646440

Similar Datasets

Project description:ObjectiveThe present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia.MethodsOne hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS). Rating scales and safety assessments (RSESE, BARS, UKU) were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8.ResultsOne hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group). PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003) and week 8 (P = 0.007) compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005) and week 8 (P< 0.001) compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001), week 4 (P< 0.001), week 6 (P< 0.001) and week 8 (P< 0.001) compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups.ConclusionsAdjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia.Trial registrationchictr.org ChiCTR-IOR-15006278.

Project description:BACKGROUND:The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance treatment for BP-I. METHODS:This open-label multicenter study evaluated the effectiveness of AOM 400 as maintenance treatment for BP-I by assessing safety and tolerability (primary objective) and efficacy (secondary objective). The study enrolled AOM 400-naive ("de novo") patients as well as AOM 400-experienced ("rollover") patients with BP-I from a lead-in randomized, placebo-controlled clinical trial that demonstrated the efficacy of AOM 400 in the maintenance treatment of BP-I (Calabrese et al. in J Clin Psychiatry 78:324-331, 2017). Safety variables included frequency and severity of treatment-emergent adverse events (TEAEs) and TEAEs resulting in study discontinuation. Efficacy was assessed by the proportion of patients maintaining stability throughout the maintenance phase, as well as mean changes from baseline in Young Mania Rating Scale (YMRS), Montgomery-Asberg Depression Rating Scale, and Clinical Global Impressions for Bipolar Disorder-Severity of Illness Scale (CGI-BP-S) total scores. Patient acceptability and tolerability of treatment was assessed using the Patient Satisfaction with Medication Questionnaire-Modified. RESULTS:Of 464 patients entering the maintenance phase, 379 (82%) were de novo and 85 (18%) were rollover. TEAEs were more common in de novo than rollover patients. The overall discontinuation rate due to TEAEs was 10.3% (48/464). Improvements in YMRS and CGI-BP-S total scores were maintained during the study, and the vast majority of both de novo (87.0%) and rollover (97.6%) patients maintained stability through their last visit. Overall, the need for rescue medication during the maintenance phase was minimal (<?10% of patients). Patient satisfaction levels were high, with both de novo and rollover patients rating the side effect burden of AOM 400 as greatly improved relative to previous medications. CONCLUSION:AOM 400 was safe, effective, and well tolerated by both de novo and AOM 400-experienced patients with BP-I for long-term maintenance treatment. Trial registration ClinicalTrials.gov, NCT01710709.

Project description:Abstract Objectives Stevia is a non-nutritive sweetener providing sweet taste with zero calories that could constitute an effective strategy toward sugar reduction. This study tested the effects of daily consumption of stevia drops on glycemia, body weight (BW) and energy intake in healthy normal weight adults, non-habitual consumers of non-nutritive sweeteners. Methods Twenty eight healthy participants were randomly assigned to the stevia group (n = 14, mean age: 25 ± 5.5 y, mean body mass index: 22 ± 1.8 kg/m2) and were required to consume 5 drops of a commercially available stevia extract twice daily along with their habitual drinks, or to the control group (n = 14, 25 ± 4.2 y, 21 ± 1.5 kg/m2) and were instructed not to change anything in their diet for 12 weeks. Both groups were encouraged to maintain their usual diet and physical activity habits. At baseline and week 12, glucose response to an oral glucose tolerance test (OGTT) was measured; BW and energy intake were assessed at baseline, week 6 and week 12. Results There was no significant difference in glucose response to the OGTT over the 12 weeks in any study group. However, there was a significant main effect of participant group on BW change over the 12 weeks (F(1, 26) = 5.56, P = 0.026), showing that stevia consumption prevented weight gain (ΔWeight at week 12 = −0.22 ± 0.32 kg for stevia, +0.89 ± 0.39 kg for the control group). Energy intake was significantly decreased between baseline and week 12 in the stevia group (ΔEnergy at week 12 = −344 ± 80.6 kcal, P = 0.003), however no change in energy intake was found in the control group (ΔEnergy = +13.6 ± 125 kcal, P = 0.973). Conclusions These results suggest that daily consumption of stevia in real-life doses does not affect glycemia in healthy normal-weight individuals, but could aid toward weight maintenance and moderation of energy intake. More research is warranted to explore these promising findings further in individuals with overweight/obesity and/or individuals with impaired glucose tolerance (i.e., pre-diabetes/diabetes). Clinicaltrial.gov identifier: NCT03993418. Funding Sources This project has received a N8 AgriFood Pump Priming Award. Ms Stamataki has a BBSRC DTP Case Studentship.

Dataset Information

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

Background

Aim

Methods

Results

Conclusions

Trial registration

Publications

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets